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Abstract: The central nervous system (CNS) depressant and anticonvulsant 
activities of citronellal (CT) were investigated in animal models. The CT in doses 
of 100, 200 and 400 mg/kg injected by i.p. route in mice caused a significant 
decrease in the motor activity of animals when compared with the control group. 
The highest dose of CT significantly reduced the remaining time of the animals on 
the Rota-rod apparatus up to 2 h. Additionally, CT at doses 100, 200 and 400 mg/
kg (i.p.) was also capable to promote an increase of latency for development of 
convulsions induced by pentylenetetrazole (PTZ). It was efficient in prevents the 
tonic convulsions induced by maximal electroshock (MES) in doses of 200 and 
400 mg/kg, resulting in 30 and 40% of protection, respectively. This compound 
was also capable to promote an increase of latency for development of convulsions 
induced by picrotoxin (PIC) at 400 mg/kg. In the same way, the anticonvulsant 
effect of CT was affected by pretreatment with flumazenil, a selective antagonist 
of benzodiazepine site of GABAA receptor. These results suggest a possible CNS 
depressant and anticonvulsant activities.
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Introduction
 Numerous herbal medicines are recognized 
to have activity on the central nervous system (CNS), 
and they have at least a hypothetical potential to 
affect chronic conditions, such as anxiety, depression, 
headaches or epilepsy, which do not respond well to 
conventional treatments (Carlini, 2003). An increasing 
number of studies have demonstrated that essential 
oils derived from plants exhibit a variety of biological 
properties, such as anticonvulsant (Quintans-Júnior et 
al., 2008a), analgesic (Almeida et al., 2001) and Central 
Nervous System (CNS) activities (Carlini, 2003; Silva 
et al., 2007). Monoterpenes are the primary components 
of essential oils and the effects of many herbal medicines 
have been attributed to them (Gherlardini et al., 2001; 
De Sousa et al., 2006).
 Currently, several monoterpenes have been 
reported to have neuroactive properties. Their 
actions in experimental animal models have been 
mainly linked to protection against pain (Guimarães 
et al., 2010; Quintans-Júnior et al., 2010a), anxiety 
(Silva et al., 2007), insomnia (Buchbauer et al., 
1992) and convulsion (De Sousa et al., 2006, 2007; 
Silva et al., 2009). Therefore, citronellal (CT) (1) 
is a monoterpene, predominantly formed by the 
secondary metabolism of plants. It is typically 
isolated as a non-racemic mixture of its R and 
S enantiomers by steam distillation or solvent 
extraction from the oils of Corymbia citriodora Hill 
and Johnson (former Eucalyptus citriodora Hook) 
Cymbopogon nardus and C. winterianus (Lenardão 
et al., 2007). Recently, in a preliminary behavioral 
screening realized with the essential oil of the C. 
winterianus, our group demonstrates CNS depressant 
and anticonvulsant activities in rodents (Quintans-
Júnior et al., 2008b). Melo et al., (2010) and 
Quintans-Júnior et al., (2010a, 2011) demonstrated 
an antinociceptive effect of the CT using unspecific 
and specific tests.
 CT is one of the major components of essential 
oil of the C. winterianus and the role of CT in CNS 
property is not yet well established. In consequence 
of it, we decided to assess the CNS effects of this 
compound in rodents.
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Materials and Methods
Drugs
 The drugs used were: pentylenetetrazole (PTZ), 
picrotoxin (PIC), phenytoin (PHE), polyoxyethylene-
sorbitan monolated (Tween 80) purchased by Sigma 
(USA) and diazepam (DZP) by Cristália (Brazil). The 
citronellal (1) used was a racemic mixture of R and S 
enantiomers [(RS)-(±)-citronellal] (Dierberger, Brazil) 
with 98% purity. PTZ, PIC, PHE, DZP and CT were 
administrated by intraperitoneally route (i.p.) at a dose 
volume of 0.1 mL/10 g. 
Animals
 Male Swiss mice (30-35 g), 2-3 months of 
age, were used throughout this study. The animals were 
randomly housed in appropriate cages at 25±2 ºC on a 
12 h light/dark cycle (lights on 6:00-18:00 h) with free 
access to food (Purina®) and water. All experiments 
were carried out between 9:00 and 16:00 h in a quiet 
room. Experimental protocols and procedures were 
approved by the Animal Care and Use Committee at the 
Federal University of Sergipe (CEPA/UFS # 12/08). 
Behavioral effects 
 Behavioral screening of the mice (n=6, per 
group) was performed following parameters described 
by Almeida et al., (1999) and animals were observed at 
0.5, 1, 2 and 4 h after intraperitoneal (i.p.) administration 
of CT (100, 200 and 400 mg/kg, i.p.).
Locomotor activity
 Mice were divided into four groups of eight 
animals each. Vehicle (saline/Tween 80 0.2%; control 
group) and CT (100, 200 and 400 mg/kg, i.p.) were 
injected. The spontaneous locomotor activity of the 
animals was assessed in a cage activity (50 × 50 × 50 
cm) in 0.5, 1 and 2 h after administration (Asakura et 
al., 1993).
Motor coordination test (Rota-rod test)
 A Rota-rod tread mill device (AVS®, Brazil) 
was used for the evaluation of motor coordination 
(Perez et al., 1998). Initially, the capable mice to remain 
on the Rota-rod apparatus longer than 180 s (9 rpm) 
were selected 24 h before the test. Thirty minutes after 
the administration of either CT (100, 200 and 400 mg/
kg, i.p.), vehicle (saline/Tween 80 0.2%; control group) 
or DZP (1.5 mg/kg, i.p.), each animal was tested on the 
Rota-rod apparatus and the time (s) remained on the bar 
for up to 180 s was recorded after 0.5, 1 and 2 h.
Pentylenetetrazole (PTZ)-induced convulsions
 PTZ was used to induce clonic convulsions 
(Smith et al., 2007). Mice were divided into five groups 
(n=8, per group). The first group served as control and 
received vehicle (Tween 80 0.2% in distilled water, the 
solvent for CT), while the second group was treated 
with DZP (2 mg/kg, i.p.). The remaining groups 
received an injection of CT (100, 200 and 400 mg/
kg, i.p.). After 0.5 h of drug administration, the mice 
were treated with PTZ (i.p.) at a dose of 60 mg/kg. The 
latency and percent of inhibition clonic convulsions 
were registered. The incidence of deaths was noted 
until 48h after the injection of PTZ.
Effects of flumazenil on PTZ-induced convulsion 
 The effect of selective GABAA-BZD receptor 
antagonist, flumazenil (FLU) (File & Pellow, 1986), 
on the anticonvulsant activity of CT was investigated. 
This protocol was performed according to Quintans-
Júnior et al. (2010b). In the experimental groups, mice 
were given FLU (10 mg/kg, i.p.) 20 min before the 
administration of CT (400 mg/kg, i.p.), 0.5 h before 
the injection of PTZ. In the standard group, the animals 
received FLU 20 min before the administration of 
DZP (2 mg/kg, i.p.) (0.5 h before the injection of PTZ) 
(Quintans-Júnior et al., 2010b). The anticonvulsant 
activity of CT and DZP in mice pretreated with FLU 
was assessed.
Picrotoxin (PIC)-induced convulsion
 The method has been described previously 
(Lehmann et al., 1988; Ngo Bum et al., 2001). Animals 
were divided into five groups (n=8, per group). The 
control group received vehicle and standard group was 
treated with DZP (2 mg/kg, i.p.). The remaining groups 
were treated with 100, 200 and 400 mg/kg of CT (i.p.). 
After 0.5 h of drug administration, the mice were treated 
with PIC at a dose of 8 mg/kg (i.p.). Immediately after 
the injection of the convulsant, mice were individually 
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placed in plastic boxes and observed for the time 
onset of clonic convulsion (latency), percent clonic 
convulsion and deaths. The incidence of deaths was 
noted until 48 h after the injection of PIC.
Maximal electroshock (MES) test
 MES produces reproducible tonic 
convulsions characterized by tonic hindlimb extension 
(THE) (Oliveira et al., 2001). In this experiment, 
electroconvulsive shock (130 V, 150 pulses/s, 0.5 
s) was delivered through auricular electrodes (ECT 
UNIT 7801- Ugo Basile) to induced THE. Mice were 
divided into five groups (n=10, per group). The first 
group served as control and received vehicle, while 
the second group was treated with PHE (25 mg/kg, 
i.p.). The others groups received an injection of CT, 
similarly before experiment. After 0.5 h all groups 
received electroconvulsive shock. The animals that did 
not exhibit THE were considered protected (Tortoriello 
& Ortega, 1993).
Statistical analysis
 The data obtained were evaluated by one-way 
analysis of variance (ANOVA) followed by Dunnett`s 
test. The incidence (%) of clonic or tonic-clonic 
convulsions as well as the mortality were evaluated by 
Fisher`s Exact Test. Differences were considered to be 
statistically significant when p<0.05.
Results
Behavioral effects 
 CT at doses of 100, 200 and 400 mg/kg (i.p.) 
revealed behavioral changes in animals 0.5, 1, 2 and 
4 h after treatment: decrease of spontaneous activity, 
palpebral ptosis, ataxia, analgesia, and sedation. 
Behavioral changes were more evident in the first 2 h. 
These effects were dose-dependent.
Locomotor activity
 In doses of 100, 200 or 400 mg/kg, CT caused 
a significant decrease of ambulation (number of 
crossings) at 0.5, 1 and 2 h after administration (Figure 
1). 
Motor coordination (Rota-rod test)
 In this test, 0.5 and 1 h after administration of 
CT, only at the dose of 400 mg/kg (i.p.) the remaining 
time of animals on the Rota-rod apparatus was 
significantly reduced (Figure 2).
Anticonvulsant activity
 Table 1 shows that in the control group the 
PTZ consistently induced clonic convulsions in 100% 
of mice. CT (100, 200 and 400 mg/kg, i.p.) delayed the 
onset of PTZ-induced tonic convulsion significantly. 
CT (400 mg/kg, i.p.) protected 80% (p<0.001) of mice 
against the convulsion. DZP (2 mg/kg, i.p.) completely 
protected the animals against the tonic convulsion 
elicited by PTZ.
 As can be seen in Table 1, the administration of 
FLU (10 mg/kg, i.p.) antagonized the effect of CT (400 
mg/kg, i.p.) and DZP (2 mg/kg, i.p.) in the prolongation 
of convulsion latency.
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Figure 1. Effect of citronellal (CT, 100, 200 and 400 mg/kg, i.p.) or diazepam (DZP, 1.5 mg/kg, i.p.) on locomotor activity of mice. 
The parameters evaluated were the total number of pulses of crossings in activity cage. Values are the mean±SEM for eight mice 
(per group). *p<0.05 or **p<0.001 as compared to control (vehicle), one way ANOVA followed by Dunnet’s test.
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Table 1. Effect of citronellal (CT) on PTZ-induced convulsion 
in mice.
Treatment Dose  (mg/kg) Latency (s)
a % Inhibition 
of convulsion
% Inhibition 
of death
Vehicle - 126.3±11.9 0 0
CT 100 329.0±122.6d 0 0
CT 200 575.8±88.0e 20 40b
CT 400 852.5±47.5f 80c 0
CT+FLU 400 + 10 141.8+38.9 0 20
DZP 2 900.0±0.0f 100c 100c
DZP+FLU 2+10 131.2+25.2 0 10
 When given i.p. only the highest dose of CT 
(400 mg/kg, i.p.) increased the latency for convulsions 
induced by PIC, significantly different from control 
(p<0.001) (Table 2).
 On MES-induced convulsion, CT (200 and 400 
mg/kg, i.p.) was effective to reduce the occurrence of 
tonic convulsion in 30 and 40% of animals, respectively 
(Figure 3).
Discussion
 In the present study, the CNS depressant and 
anticonvulsant activities of CT were investigated 
in different animal models. Initially, to assess the 
behavioral effects, the mice were treated with different 
doses of CT (100, 200 and 400 mg/kg, i.p.) and presented 
alterations, such as reduction of the ambulation, 
palpebral ptosis, ataxia and sedation. These behavioral 
changes suggest a possible effect on CNS and are 
similar to drugs that reduce the CNS activity (Morais 
et al., 2004; Netto et al., 2009).
Table 2. Effect of citronellal (CT) on PIC-induced convulsion 
in mice.
Treatment Dose  (mg/kg) Latency (s)
a % Inhibition 
of convulsion
% Inhibition 
of death
Vehicle - 496.2±24.5 0 0
DZP 2 1200.0±0.0b 100d 100d
CT 100 498.5±21.01 0 0
CT 200 567.5±45.9 20 20
CT 400 1163.7±19.3b 50c 40c
DZP 2 900.0±0.0f 100c 100c
DZP+FLU 2+10 131.2+25.2 0 10
 CT at all doses caused a significant reduction 
of ambulation of animals in the test of spontaneous 
movement after 0.5, 1 and 1.5 h of its administration in 
the doses of 100, 200 and 400 mg/kg, that corroborates 
with the hypothesis of the CT reduces the CNS activity. 
It was reported that reduction of the ambulation of the 
animals is characteristic of psychopharmacological 
drugs (Leite et al., 2008; Carlini, 2003).
 The reduction of the locomotor activity was 
observed by many monoterpenes (Passos et al., 2009) 
and it can be due to either through an inhibitory effect 
of the CT in CNS or by muscular relaxant activity in the 
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Figure 2. Time (s) on the Rota-rod observed in mice after i.p. treatment with vehicle (control), citronellal (CT, 100, 200 and 400 
mg/kg, i.p.) or diazepam (DZP, 1.5 mg/kg, i.p.). The motor response was recorded for the following 180 s after drug treatment. 
Values are the mean±SEM for eight mice (per group). *p<0.05 or **p<0.001 as compared to control (vehicle), one way ANOVA 
followed by Dunnet’s test.
n=8; aValues represent mean±SEM; bp<0.05 (Fisher`s test), significantly 
different from control; cp<0.001 (Fisher`s test), significantly different 
from control; dp<0.05 (one-way ANOVA and Dunnett`s test), significantly 
different from control; ep<0.01 (one-way ANOVA and Dunnett`s test), 
significantly different from control; fp<0.001 (one-way ANOVA and 
Dunnett`s test), significantly different from control.
n=8; aValues represent mean±SEM; bp<0.001 (one-way ANOVA and 
Dunnett`s test), significantly different from control; cp<0.01 (Fisher`s 
test), significantly different from control; dp<0.001 (Fisher`s test), 
significantly different from control.
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system, probably through a competitive agonist action 
in the BZD site of the GABA receptors. The significantly 
effect on the motor coordination, on high doses, might 
support this theory, as GABAergic drugs usually are 
sedative (Pedersen et al., 2009).
 According to Nicoll (2001), PIC, a GABAA-
receptor antagonist, produces seizures by blocking the 
chloride-ion channels linked to GABAA-receptors, thus 
preventing the entry of chloride ions into the brain 
and, consequently, inhibitory transmission in the brain 
(Löscher & Schmidt, 2006). Therefore, the findings 
of the present study suggest that CT (400 mg/kg, i.p.) 
might have inhibited and/or attenuated the PIC-induced 
convulsions of mice by interfering with GABAergic 
neurotransmission (Oliveira et al., 2001). 
 MES test is the most frequently used as an 
animal model for identification of anticonvulsant 
activity of drugs for the “grand mal” (Oliveira et al., 
2001; Smith et al., 2007). All the currently available 
antiepileptic drugs (AEDs), which are clinically 
effective in the treatment of generalized tonic-clonic 
convulsions, such as phenobarbital, lamotrigine and 
carbamazepine, are effective in the MES test (Löscher, 
1998). Our results suggest that CT (in high doses) 
may prove to be important chemical leads for future 
antiepileptic drugs. 
 In conclusion, the results suggest a possible 
depressant CNS and anticonvulsant effects of CT. The 
precise mechanisms of possible behavioral effects of CT 
are not clear. However, GABAergic neurotransmitter 
system might be involved. Nevertheless, more studies 
will be required for elucidation this effect and neuronal 
mechanisms relationship.
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